Abstract : Simple Summary It has been a continuous effort to develop innovative targeted cancer treatments to overcome the non-specific toxicity associated with chemotherapy. Antibody-drug conjugates (ADCs) highlight the clinical benefits of specifically delivering drugs to cancer cells via targeting agents. Aptamers are high-affinity ligands that can be made synthetically and employed as targeting molecules in place of antibodies.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile